Long-Term Safety of Teriflunomide in Multiple Sclerosis Patients: Results of Prospective Comparative Studies in Three European Countries.

Magyari M, Koechlin A, Duclos A, Kopp TI, Allaoui EM, Polazzi S, Seeldrayers P, Autier P

Open source

DOI
10.1002/pds.5866
Published
2024 Jul
Container
Pharmacoepidemiology and drug safety
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/pds.5866,
  title = {Long-Term Safety of Teriflunomide in Multiple Sclerosis Patients: Results of Prospective Comparative Studies in Three European Countries.},
  author = {Magyari M and Koechlin A and Duclos A and Kopp TI and Allaoui EM and Polazzi S and Seeldrayers P and Autier P},
  year = {2024},
  journal = {Pharmacoepidemiology and drug safety},
  doi = {10.1002/pds.5866},
  url = {https://doi.org/10.1002/pds.5866}
}

RIS

TY  - JOUR
TI  - Long-Term Safety of Teriflunomide in Multiple Sclerosis Patients: Results of Prospective Comparative Studies in Three European Countries.
AU  - Magyari M
AU  - Koechlin A
AU  - Duclos A
AU  - Kopp TI
AU  - Allaoui EM
AU  - Polazzi S
AU  - Seeldrayers P
AU  - Autier P
PY  - 2024
JO  - Pharmacoepidemiology and drug safety
DO  - 10.1002/pds.5866
UR  - https://doi.org/10.1002/pds.5866
ER  - 

APA

M, M., A, K., A, D., TI, K., EM, A., S, P., P, S., & P, A. (2024). Long-Term Safety of Teriflunomide in Multiple Sclerosis Patients: Results of Prospective Comparative Studies in Three European Countries.. Pharmacoepidemiology and drug safety. https://doi.org/10.1002/pds.5866

Source records